Scynexis: Stock Has Been Punished Enough: GSK Partnership, Future Revenue Potential And 2-Year Cash Runway Warrant A 'Buy'
Seeking Alpha,
Follow Summary Scynexis is developing a novel antifungal category called "fungerps" to address antifungal resistance.